Aquablation therapy continues to gain traction within urology services as a precise, robot-assisted treatment option for benign prostatic hyperplasia (BPH), reflecting a broader shift toward minimally invasive, technology-driven care pathways.
Aquablation is a waterjet-based surgical technique that combines real-time imaging with robotic execution to remove obstructive prostate tissue while preserving surrounding anatomy. The procedure is designed to deliver consistent outcomes across a wide range of prostate sizes, with a focus on procedural accuracy, reproducibility, and efficient operating theatre workflows.
Recent clinical adoption has highlighted Aquablation’s suitability for modern BPH services, including its role in streamlined inpatient and day-case pathways. The technology enables surgeons to plan resections visually and execute them with robotic precision, reducing operator variability and supporting predictable results.
Clinical experience has demonstrated that Aquablation can be effectively integrated into both NHS and private practice environments. Its profile has grown particularly in centres seeking alternatives to traditional resection or laser techniques, while maintaining strong symptom relief and favourable functional outcomes.
Jeremy Nettleton, Consultant Urologist, has been closely involved in advancing contemporary BPH treatment strategies and has contributed to the wider clinical conversation around adopting innovative surgical technologies that align with evolving patient expectations and service delivery models.
Aquablation therapy is developed by PROCEPT BioRobotics and is supported by an expanding body of international clinical evidence evaluating its safety, efficacy, and long-term outcomes.
As healthcare systems continue to prioritise minimally invasive procedures, reduced length of stay, and patient-centred outcomes, Aquablation is increasingly positioned as a key component in the future landscape of BPH management.
